Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 microg/Week) and Ribavirin (1600 mg/Day) With Epoetin beta Support (450 IU/kg/Week)

Trial Profile

Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a (40 KD) (270 microg/Week) and Ribavirin (1600 mg/Day) With Epoetin beta Support (450 IU/kg/Week)

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Therapeutic Use
  • Acronyms CORAL2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual end date changed from Oct 2007 to Mar 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top